-
公开(公告)号:EP3718545A1
公开(公告)日:2020-10-07
申请号:EP18883950.0
申请日:2018-11-28
发明人: UENO, Hiroyuki , HOSHINO, Takuya
IPC分类号: A61K31/4245 , A61K45/00 , A61P35/00 , A61P43/00 , C07D249/04
摘要: The present invention provides a method of enhancing an antitumor effect by a compound strongly inhibiting ribonucleotide reductase (RNR) or a salt thereof.
A combination formulation involving combined administration of a sulfonamide compound represented by Formula (I) [In the formula, X 1 represents an oxygen atom or the like; X 2 represents an oxygen atom; X 3 represents -NH-; X 4 represents a hydrogen atom or the like; R 1 represents -C(R 11 ) (R 12 )- or the like; R 11 and R 12 are the same or different and each represents a hydrogen atom or the like; R 2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R 3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R 4 represents a hydrogen atom or the like] or a salt thereof, having RNR inhibitory activity, and other antitumor agent(s).-
公开(公告)号:EP3466934A1
公开(公告)日:2019-04-10
申请号:EP17806708.8
申请日:2017-05-30
发明人: MIYAHARA, Seiji , UENO, Hiroyuki , HARA, Shoki , OGINO, Yoshio
IPC分类号: C07D249/04 , A61K31/4245 , A61K31/428
摘要: The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.
A compound represented by Formula (I) [wherein, X 1 represents an oxygen atom or the like; X 2 represents an oxygen atom; X 3 represents -NH-; X 4 represents a hydrogen atom or the like; R 1 represents -C(R 11 )(R 12 )- or the like; R 11 and R 12 are the same or different and each represents a hydrogen atom or the like; R 2 represents an optionally substituted C 6 -C 14 aromatic hydrocarbon group or the like; R 3 represents an optionally substituted C 6 -C 14 aromatic hydrocarbon group or the like; R 4 represents a hydrogen atom or the like] or a salt thereof.
-